First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports
TAGRISSO® (osimertinib) | FLAURA
Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L) - Clinical Lung Cancer
Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset - Journal of Thoracic Oncology
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis - Annals of Oncology
VisualAbstract: Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | 2 Minute Medicine
Jiang Xiaoming (@Jiang_Macau) / Twitter
Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation - Lung Cancer
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis - Annals of Oncology
Landmark overall survival at 2 years and 2.5 years in patients treated... | Download Scientific Diagram
Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations - Clinical Lung Cancer
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status - Journal of Thoracic Oncology
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study | SpringerLink
Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer - European Journal of Cancer
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer | Business Wire
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer | NEJM
A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903 - ESMO Open
NEJM on Twitter: "Original Article: Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer (FLAURA) https://t.co/nM2Vzi5MTb #ESMOAsia17 https://t.co/qwumF8zpfz" / Twitter
Overall survival in patients treated with osimertinib versus... | Download Scientific Diagram
Metastatic NSCLC Efficacy of TAGRISSO® (osimertinib)
EGFR-positive tumors: the issue of optimal therapy across several lines - memoinOncology
EGFR-mutant lung cancer: sequencing as a major topic in light of new data - memoinOncology
Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset | Semantic Scholar
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
